CSV October 31, 2022 through October 31, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ENOXAPARIN	SPECIFIC	*USP40–NF35*	3982	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First*	Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SODIUM INJECTION	TESTS/*Anti-Factor IIa Activity*						*Supplement to USP41–NF36*	*Standard solutions*: Dilute USP Enoxaparin Sodium Solution for Bioassays RS with *pH 7.4 buffer* to obtain four dilutions having concentrations in the range between 0.015 and 0.075 IU of Anti-Factor IIa activity/mL.
ISOSORBIDE DINITRATE EXTENDED-RELEASE TABLETS	*Dissolution <711>/Test 2*	*USP40–NF35*	4710	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1: Change *Buffer solution* and *Mobile phase*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution* and *Mobile phase*—Prepare as directed in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Assay*. AND Line 1 of *Chromatographic system*: Change (see *Chromatography <621>*)—Proceed as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: (see *Chromatography <621>*)—Proceed as directed in the *Assay*.
MYCOPHENOLATE SODIUM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5256	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
MONOBASIC POTASSIUM PHOSPHATE	IMPURITIES/*Arsenic, Method I <211>*	*USP40–NF35*	7847	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1: Change 3 µg/g to: NMT 3 µg/g
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS	ASSAY/*Procedure*	*Revision Bulletin (Official April 01, 2017)*	Online	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Chromatographic system*/*Column*: Change 10-µm to: 5-µm AND In the variable

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								definition list in *Analysis*: Change r_U = citrate peak area from the *Sample solution* r_S = citrate peak area from the *Standard solution* to: r_U = citric acid peak area from the *Sample solution* r_S = citric acid peak area from the *Standard solution* AND Change M_{r2} = molecular weight of citrate ($C_6H_5O_7$), 189.10 to: M_{r2} = molecular weight of citric acid ($C_6H_8O_7$), 192.13
CALCIPOTRIE	IM	*USP40–NF35*	3114	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First*	Footnote a of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NE OINTMENT	PUR ITIES/*Organic Impurities*						*Supplement to USP41–NF36*	*Table 1*: Change (5*Z*,7*Z*,22*E*,24*R*)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol. to: (5*Z*,7*Z*,22*E*,24*S*)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1?,3?,24-triol.
ISOSORBIDE DINITRATE EXTENDED-RELEASE CAPSULES	*Assay*	*USP40–NF35*	4708	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluted Isosorbide Dinitrate. to: *Buffer solution* —Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temper ature,dilute with water to 1000 mL, mix, degas,and filter. Make

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution* —Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep aration*—Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Chromatographi c system* (see *Chromatograph y <621>*)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than 2%. [NOTE—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								The relative retention times for isosorbide mononitrates, if present, are about 0.38.] *Procedure*—Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
MYCOPHENOLATE MOFETIL FOR INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5250	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Mycophenolate Mofetil Related Compound B RS: Change (*RS*)-7-Hydroxy-5-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H*-isobenzofuran-1-one.
PEMETREXED FOR INJECTION	ASSAY/*Procedure/Analysis*	*USP40–NF35*	5590	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	In the variable definition list: Change M_{r2} = molecular weight of pemetrexed disodium, 597.49 to: M_{r2} = molecular weight of pemetrexed disodium (anhydrous),

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUVOXAMINE MALEATE	IMPURITIES/*Organic Impurities*/*Table 1*	*Second Supplement to USP40–NF35*	8797	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	473.37 Footnote b:Change 5-Methoxy-1-[4-(trifluoromethyl) phenyl]-1-pentanone (*E*)-*O*-[2-[(2-succinyl) amino]ethyl]oxime. to: (*E*)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone *O*-[2-[(2-succinyl) amino]ethyl]oxime. AND Footnotes c– g: Delete the space before oxime
REAGENTS	REAGENT SPE *Bromelain*/*Activity*	*USP40–NF35*	2339	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Buffer solution*: Change Add 150 mg of sodium chloride to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Determination							Add 150 g of sodium chloride
FENOLDOPAM MESYLATE	*USP Reference standards <11>*	*USP40–NF35*	4159	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Fenoldopam Related Compound A RS: Change 1-Methyl-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-, methanesulfonate (salt). $C_{17}H_{18}ClNO_3 \cdot CH_4SO_3$ 415.89 to: 6-Chloro-1-(4-hydroxyphenyl)-3-methyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepine-7,8-diol hydrochloride (*N*-Methyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphe

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								nyl)-1*H*-3-benzazepine-7,8-diol hydrochloride). $C_{17}H_{19}ClNO_3 \cdot HCl$ 356.24
MEBENDAZOLE	IMPURITIES/*Organic Impurities*/*Table 2*	*USP40–NF35*	4968	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Change footnotes [d]Ethyl 5-benzoyl-1-methylbenzimidazol-2-ylcarbamate. [e]Methyl 5-(4-toluoyl)-1-methylbenzimidazol-2-ylcarbamate. to: [d]Ethyl (5-benzoyl-1*H*-benzimidazol-2-yl)carbamate. [e]Methyl 5-(4-toluoyl)-1*H*-benzimidazol-2-ylcarbamate.
MYCOPHENOL	IM	*USP40–NF35*	5256	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First*	Footnote a of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATE SODIUM	PUR ITIES/*Organic Impurities*						*Supplement to USP41–NF36*	*Table 2*: Change (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H* -isobenzofuranyl-1-one. to: (*RS*)-7-Hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3*H* -isobenzofuran-1-one.
CANDESARTAN CILEXETIL TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP40–NF35*	8730	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Candesartan Cilexetil Related Compound D RS: Change 1-{[(Cyclohexyloxycarbonyloxy)carbonyl]oxy}ethyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								H -tetrazol-5-yl)biphenyl-4-yl]methyl}-2-oxo-2,3-dihydro-1*H* -benzimidazole-4-carboxylate. to: 1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl
ENALAPRIL MALEATE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Table 1*	*USP40–NF35*	3971	29-Sep-2017	1-Oct-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	*H* -tetrazol-5-yl)-[1,1'-biphenyl]-4-yl}methyl)-2-oxo-2, 3-dihydro-1*H* -benzimidazole-4-carboxylate. Row 3 of Column 3: Change 100 to: 200

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ONDANSETRON INJECTION	*USP Reference standards <11>*	*USP40–NF35*	5443	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
ROCURONIUM BROMIDE	IMPURITIES/*Limit of 2-Propanol/Analysis*	*USP40–NF35*	6066	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of the variable definition list: Change r_U = peak response of any impurity from the *Sample solution* r_S = peak response of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								rocuronium bromide from the *Dilute standard solution* to: r_U = peak response of 2-propanol from the *Sample solution* r_S = peak response of 2-propanol from the *Dilute standard solution*
OIL- AND WATER-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USP40–NF35*	7290	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 23 of *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Dilute a volume of this solution to: *Sample solution*: Dilute a volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione/Sample solution*:Change in the directions for the *Sample solution* to: in the directions for the *Sample stock solution*
MONOSACCHARIDE ANALYSIS	PROCEDURES */Procedure 3: Enzymatic Hydrolysis and Analysis by RP-HPLC of DMB-labeled Sialic Acids*	*First Supplement to USP40–NF35*	8059	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 6 of *Analysis*: Change (1 M = 1nmol/mL). to: (1 µM = 1nmol/mL).
LEVOTHYROXIM		*First*	8328	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First*	Line 4 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NE SODIUM TABLETS	PURITIES/*Limit of Liothyronine Sodium*	*Supplement to USP40–NF35*					*Supplement to USP41–NF36*	*Analysis*: Change Calculate the percentage of levothyroxine sodium ($C_{15}H_{11}I_3NNaO_4$) to: Calculate the percentage of liothyronine sodium ($C_{15}H_{11}I_3NNaO_4$)
DOXAZOSIN MESYLATE	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*USP40–NF35*	3874	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Resolution*: Change NLT 4 to: NLT 2
PERPHENAZINE	IMPURITIES/*Organic Impurities*/*Chromatographic system*	*USP40–NF35*	5649	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Column*: Change 4.6-mm to: 4.0-mm
OIL-SOLUBLE VITAMINS WITH	STRENGTH	*USP40–NF35*	7265	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A*/*Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MINERALS CAPSULES								*solution*: Change *Sample solution* to: *Sample stock solution* AND Line 21 of *Sample solution*: Change Further dilute this solution to: *Sample solution*: Dilute the *Sample stock solution* AND Line 2 of *Vitamin D*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 2 of *Vitamin E*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Phytonadione (Vitamin K_1)*:Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Beta Carote ne*/*Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change as directed for the *Sample solution* to: as directed for the *Sample stock solution*
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP40–NF35*	7375	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 16 of *Sample solution*: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								stock solution AND Line 2 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Vitamin E, Method 1*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample stock solution AND Line 2 of *Phytonadione, Method 1*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution*
ACETAMINOPHEN AND CODEINE PHOSPHATE TABLETS	PERFORMANCE TESTS	*First Supplement to USP40–NF35*	8202	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Dissolution <711>*/*Analysis*: Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled amount of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acetaminophen AND In the second Calculate statement in *Uniformity of Dosage Units <905>/ Procedure for content unifor mity/Analysis*: Change Calculate the quantity, in mg/mL, of the labeled amount of codeine phosphate to: Calculate the quantity, in mg, of codeine phosphate
TIMOLOL MALEATE	MULTIPLE SECTIONS	*Second Supplement to USP40–NF35*	Online	28-Jul-2017	1-Aug-2017	*USP41–NF36*	*USP41–NF36*	The version of the Timolol Maleate monograph which appeared in the *Second Supplement to*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP 40–NF 35 did not include the revisions approved in the version appearing in the *First Supplement to USP 40–NF 35*. The version appearing in the *First Supplement* should be used. The file as it should have appeared in the *Second Supplement* is attached to the compendial notice found at http://www.uspnf.com/notices/second-supplement-usp-40-nf-35-online-timolol-maleate.
ONDANSETRON ORAL SOLUTION	*USP Reference standards <11>*	*USP40–NF35*	5444	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL-SOLUBLE VITAMINS CAPSULES	STRENGTH	*USP40–NF35*	7248	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride. Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 23 of *Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Dilute a volume of this solution to: *Sample solution*: Dilute a volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Vitamin E, Method 1*/*Sample solution*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 1 of *Phytonadione/Sample solution*:Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution*
OIL- AND WATER-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP40–NF35*	7318	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1*/*Sample solution*: Change *Sample solution* to: *Sample stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution AND Line 16 of *Sample solution*: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 1 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method 1*/*Sample solution*: Change retained as specified in the directions for the *Sample solution* to: retained as specified in the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directions for the *Sample stock solution*
NEOTAME	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP40–NF35*	8485	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Neotame Related Compound A RS: Change *N*-[3,3-Dimethylbutyl)-L-?-aspartyl]-L-phenylalanine. to: *N*-[*N*-(3,3-Dimethylbutyl)-L-?-aspartyl]-L-phenylalanine.
ONDANSETRON HYDROCHLORIDE	*USP Reference standards <11>*	*USP40–NF35*	5441	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
PROPANTHELINE BROMIDE	IMPURITIES/*Organic Impurities/ Chromatographic system*	*USP40–NF35*	5882	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Run time*: Change NMT to: NLT
OIL-SOLUBLE VITAMINS WITH MINERALS TABLETS	STRENGTH	*USP40–NF35*	7280	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A*/*Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 15 of *Sample solution*: Change Further dilute this solution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Sample solution*: Dilute the *Sample stock solution* AND Line 2 of *Vitamin D*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Vitamin E*/*Sample solution*: Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution AND Line 2 of *P hyt onadi one (Vitamin K_1)*:Change as directed for the *Sample solution* to: as directed for the *Sample stock solution* AND Line 2 of *Beta Carote ne*/*Sample solution*: Change as directed for the *Sample solution* to: as directed for the *Sample stock solution*
SHELLAC	IM PURITIES/*Limit of Chloride*	*USP40–NF35*	7869	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Control solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ERYTHROMYCIN OPHTHALMIC OINTMENT	ASSAY/ *Procedure/Analysis*	*First Supplement to USP40–NF35*	8276	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	0.1 M hydrochloric acid VS, to: 0.01 M hydrochloric acid VS, Line 9 of the third variable definition list: Change *P* = potency of erythromycin C in USP Erythromycin B RS (mg/mg) to: *P* = potency of erythromycin C in USP Erythromycin C RS (mg/mg)
VITAMIN D ASSAY	ASSAY/ *Chromatographic Methods/Procedure 8*	*USP40–NF35*	462	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	*Clean-up chromatographic system*: Add *Flow rate*: 1.1 mL/min AND *Analytical chromatographic system*: Add

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Flow rate: 1.0 mL/min
ONDANSETRON TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	5445	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 2 of USP Ondansetron Related Compound A RS: Change 3[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one. to: 3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4*H*-carbazol-4-one hydrochloride.
OIL-SOLUBLE VITAMINS TABLETS	STRENGTH	*USP40–NF35*	7258	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Vitamin A, Method 1/Sample solution*: Change *Sample solution* to: *Sample stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution AND Line 16 of *Sample solution*: Change Dilute a 10-mL volume of this solution to: *Sample solution*: Dilute a 10-mL volume of the *Sample stock solution* AND Line 2 of *Cholecalciferol or Ergocalciferol (Vitamin D), Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution AND Line 1 of *Vitamin E, Method 1*/*Sample solution*: Change Proceed as directed for the *Sample solution* to: Proceed as directed for the *Sample stock solution* AND Line 2 of *Phytonadione, Method 1*/*Sample solution*: Change retained as specified in the directions for *Sample solution* to: retained as specified in the directions for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH	*USP40–NF35*	7336	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	*Sample stock solution* Line 1 of *Vitamin A, Method 1/Sample solution*: Change *Sample solution* to: *Sample stock solution* AND Line 23 of *Vitamin A, Method 1/Sample solution*: Change Dilute a volume of this solution to: *Sample solution*: Dilute a volume of the *Sample stock solution* AND Line 2 of *Cholecalciferol or Ergocalciferol*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(Vitamin D), Method 1/*Sample solution*:Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *Vitamin E, Method 1*/*Sample solution*:Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution* AND Line 2 of *P hyt*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								onadio ne:Change prepared as directed for the *Sample solution* to: prepared as directed for the *Sample stock solution*
ACETAMINOPHEN AND CODEINE PHOSPHATE CAPSULES	PERFORMANCE TESTS	*First Supplement to USP40–NF35*	8201	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	Line 1 of *Dissolution <711>/ Analysis*:Change Determine the labeled amount of acetaminophen to: Determine the percentage of the labeled amount of acetaminophen AND In the Calculate statement of *Uniformity of Dosage Units <905>/*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POTASSIUM CITRATE EXTENDED-RELEASE TABLETS	OTHER COMPONENTS/*Content of Potassium*	*Revision Bulletin (Official April 01, 2017)*	Online	28-Jul-2017	1-Aug-2017	*USP42–NF37*	*First Supplement to USP41–NF36*	*Procedure for content unifor mity/Analysis*: Change Calculate the quantity, in mg, of the labeled amount of codeine phosphate to: Calculate the quantity, in mg, of codeine phosphate Line 1 of *Sample solution*: Change Transfer 3.0 mL of the clear filtrate, reserved from the *Assay*, to a 100-mL volumetric flask. to: *Sample stock solution*: Dilute the clear filtrate, reserved from

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Assay*, with water to obtain a solution containing about 160 µg/mL of potassium citrate monohydrate. *Sample solution*: Transfer 3.0 mL of the *Sample stock solution* to a 100-mL volumetric flask.
OLIGOSACCHARIDE ANALYSIS	SEPARATION AND IDENTIFICATION OF OLIGOSACCHARIDES	*USP40–NF35*	273	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Normal Phase Chromatography/HILIC/ Ammonium formate buffer*: Change Add *1.4 M ammonia solution* to *1.4 M formic acid solution*. to: Add *1.4 M ammonia*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution to *1.4 M formic acid solution* until a pH of 4.4 is obtained.
GLUCONOLACTONE	ASSAY/ *Procedure*	*USP40–NF35*	4412	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 5 of *Analysis*: Change Each mL of *Back-titrant* to: Each milliliter of *Titrant*
POLYETHYLENE GLYCOL 3350	SPECIFIC TESTS/ *Apparent Weight-Average Molecular Weight and Polydispersity*	*USP40–NF35*	5745	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Standard solution*: Change *Standard solution*: 1.0 mg/mL each of five polyethylene glycol standards with molecular weights of 1000,2000, 3000, 4000, and 6000 g/mol (Da) in *Mobilephase*. Pass a portion of the solution

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Standard solutions*: Prepare 1.0 mg/mL each of five polyethylene glycol standards with molecular weights of 1000,2000, 3000, 4000, and 6000 g/mol (Da) in *Mobilephase* separately in five individual flasks. Pass a portion of each solution AND Line 1 of *Analysis/Samples*: Change *Standard solution* and *Sample solution* to: *Standard solutions* and *Sample solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 3 of *Analysis*: Change Separately inject equal volumes of the *Standard solution* to: Separately inject equal volumes of the *Standard solutions*
METHYLDOPA	ASSAY/ *Procedure/ Chromatographic system*	*First Supplement to USP40–NF35*	8339	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Injection volume*: Change 1 mL to: 20 µL
ACETYLCYSTEINE SOLUTION	ASSAY/ *Procedure*	*USP40–NF35*	2586	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 3 of *Sample solution*: Change *Standard stock solution* to: *Sample stock solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PHENYTOIN ORAL SUSPENSION	IMPURITIES/*Organic Impurities*	*USP40–NF35*	5690	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 1 of *Sample solution*: Change 1 mg/mL of Oral Suspension in *Diluent* to: Nominally 1 mg/mL of phenytoin prepared as follows. Weigh and transfer a suitable volume of Oral Suspension to an appropriate volumetric flask. Add methanol to about 20% of the final flask volume and dissolve. Dilute with *Diluent* to volume. Dissolve with the aid of sonication, if necessary.
SUCROSE	SPECIFIC	*USP40–NF35*	7938	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Line 6 of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	TESTS/*Color Value/Analysis*							variable definition list: Change The absolute difference between two results is NMT 3. to: *Suitability requirements Repeatability*: The absolute difference between two results is NMT 3.
DOCETAXEL	IM PUR ITIES/*Organic Impurities, Procedure 1*	*Revision Bulletin (Official August 01, 2016)*	Online	26-May-2017	1-Jun-2017	*USP41–NF36*	*USP41–NF36*	Footnote c of *Table 2*: Change (2a*R*,4*R*,4a*S*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4, 9,11,12,12b-pentahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-cyclodeca[3,4] benz[1 ,2-*b*]oxet-5,6-dione 12b-acetate, 12-benzoate, 9-ester with (2*R*,3*S*)-*N* -formyl-3-phenyl isoserine. to: (2a*R*,4*S*,4a*S* ,6*R*,9*S*,11*S* ,12*S*,12a*R* ,12b*S*)?12b?Acetoxy? 9?(((2*R*,3*S*)?3?formamido? 2?hydroxy?3?ph enylpropanoyl)o xy)?4,6,11?trihy droxy?4a,8,13,1 3?tetramethyl?5 ?oxo?2a,3,4,4a, 5,6,9,10,11,12,1 2a,12b?dodeca hydro?1*H* ?7,11?methano cyclodeca[3,4]b enzo[1,2?*b*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]oxet-12?yl benzoate. AND Footnote d of *Table 2*: Change (2a*R*,4*R*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)-6-{[(2,2-Dichloroethoxy)carbonyl]oxy}-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,9,11,12,12b-pentahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5*H*-cyclodeca[3,4]benz[1,2-*b*]oxet-5-one 12b-acetate, 12-benzoate, 9-ester with (2*R*,3*S*)-*N*-tert-butoxycarbonyl-e-phenylisoserine.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (2a*R*,4*S*,4a*S*,6*R*,9*S*,11*S*,12*S*,12a*R*,12b*S*)?6?{[(2,2?Dichloroethoxy)carbonyl]oxy}?1,2a,3,4,4a,6,9,10,11,12,12a,12b?dodecahydro?4,9,11,12,12b?pentahydroxy?4a,8,13,13?tetramethyl?7,11?meth ano?5*H* ?cyclodeca[3,4]benz[1,2?*b*]oxet?5?one 12b?acetate, 12?benzoate, 9?ester with (2*R*,3*S*)?*N*?tert-butoxycarbonyl?3?phenylisoserine.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 18
- Page 19
- Page 20
- Page 21
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- …
- Next page Next ›
- Last page Last »